Advanced Search
MyIDEAS: Login to save this paper or follow this series

Nuove politiche per l'innovazione nel settore delle scienze della vita

Contents:

Author Info

  • Laura Magazzini

    ()
    (Department of Economics, University of Verona)

  • Fabio Pammolli

    ()
    (IMT Lucca Institute for Advanced Studies and CERM Foundation - Competitività, Regole, Mercati)

  • Massimo Riccaboni

    ()
    (IMT Lucca Institute for Advanced Studies and and Department of Managerial Economics, Strategy and Innovation, K.U. Leuven)

Abstract

Le malattie rare, che colpiscono pochi pazienti nei Paesi sviluppati nonché quelle dimenticate del Terzo Mondo, rappresentano la nuova frontiera della ricerca biomedica, una delle sfide più pressanti alla globalizzazione dei diritti dei malati, e anche un'importante occasione di crescita economica e di sviluppo industriale per l'Italia. Lo afferma uno studio del Cerm elaborato da Fabio Pammolli, il direttore del centro studi, Massimo Riccaboni e Laura Magazzini. La nostra cultura troppo spesso ci porta a scorrere le classifiche dall'alto: i libri più letti, i prodotti più venduti, i siti più vistitati, e sempre si ignora la coda della classifica pensando che sia popolata da pochi e quindi trascurabili casi. Ancor più grave è che siano ricercatori e imprenditori ad attenersi a questa regola. Il Cerm stima che 5 nuove malattie rare sono scoperte e descritte ogni settimana, e che ad oggi se ne conoscono oltre 9.000 in tutto il mondo. Sebbene considerate singolarmente le malattie rare in Europa colpiscano meno di 5 individui su 10.000, nel loro complesso esse riguardano 30 milioni di Europei e 3 milioni di Italiani, con un'incidenza sul 3-4 percento sulle nascite. Le malattie rare colpiscono per il 70 percento bambini, che nel 30 percento dei casi muoiono prima del compimento del quinto anno di età. Saper leggere le classifiche dal fondo, in un Paese in cui piccola scala e solidarietà sanno convivere, può rivelarsi una virtù, soprattutto nelle fasi di crisi economica. Occorre sostenere la ricerca che fa impresa lontano dai riflettori, per la lunga coda dei bisogni rari.

Download Info

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
File URL: http://www.cermlab.it/wp-content/uploads/cerm/wp/wpcerm-2009-03.pdf
File Function: First version, 2009
Download Restriction: no

Bibliographic Info

Paper provided by Competitività Regole Mecati (CERM) in its series Working Papers with number 03-2009.

as in new window
Length: 263 pages
Date of creation: Mar 2009
Date of revision:
Handle: RePEc:ern:wpaper:03-2009

Contact details of provider:
Postal: Via Fiorentina, 1, 53100 Siena
Phone: +39 3488120691
Email:
Web page: http://www.cermlab.it/
More information through EDIRC

Related research

Keywords: malattie rare; innovazione;

Find related papers by JEL classification:

References

References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
as in new window
  1. Moors, Ellen H.M. & Faber, Jan, 2007. "Orphan drugs: Unmet societal need for non-profitable privately supplied new products," Research Policy, Elsevier, vol. 36(3), pages 336-354, April.
  2. Lerner, Josh, 1995. "Patenting in the Shadow of Competitors," Journal of Law and Economics, University of Chicago Press, vol. 38(2), pages 463-95, October.
  3. Yamasaki, Kazuko & Matia, Kaushik & Buldyrev, Sergey V. & Fu, Dongfeng & Pammolli, Fabio & Riccaboni, Massimo & Stanley, H. Eugene, 2004. "Preferential attachment and growth dynamics in complex systems," MPRA Paper 15908, University Library of Munich, Germany, revised 06 Feb 2006.
  4. Michael Kremer, 2002. "Pharmaceuticals and the Developing World," Journal of Economic Perspectives, American Economic Association, vol. 16(4), pages 67-90, Fall.
  5. Giebe, Thomas & Grebe, Tim & Wolfstetter, Elmar, 2006. "How to allocate R&D (and other) subsidies: An experimentally tested policy recommendation," Research Policy, Elsevier, vol. 35(9), pages 1261-1272, November.
  6. Kenneth Arrow, 1962. "Economic Welfare and the Allocation of Resources for Invention," NBER Chapters, in: The Rate and Direction of Inventive Activity: Economic and Social Factors, pages 609-626 National Bureau of Economic Research, Inc.
  7. Danzon, Patricia M. & Nicholson, Sean & Pereira, Nuno Sousa, 2005. "Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances," Journal of Health Economics, Elsevier, vol. 24(2), pages 317-339, March.
  8. Laura Magazzini & Fabio Pammolli & Massimo Riccaboni & Maria Alessandra Rossi, 2009. "Patent Disclosure and R&D Competition in Pharmaceuticals," ROCK Working Papers 053, Department of Computer and Management Sciences, University of Trento, Italy, revised 11 Jun 2009.
  9. Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
  10. Frank R. Lichtenberg & Joel Waldfogel, 2003. "Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act," NBER Working Papers 9750, National Bureau of Economic Research, Inc.
  11. Richard R. Nelson, 1959. "The Simple Economics of Basic Scientific Research," Journal of Political Economy, University of Chicago Press, vol. 67, pages 297.
  12. Amy Finkelstein, 2003. "Health Policy and Technological Change: Evidence from the Vaccine Industry," NBER Working Papers 9460, National Bureau of Economic Research, Inc.
  13. Orsenigo, L. & Pammolli, F. & Riccaboni, Massimo, 2001. "Technological change and network dynamics: Lessons from the pharmaceutical industry," Research Policy, Elsevier, vol. 30(3), pages 485-508, March.
  14. Frank R. Lichtenberg & Tomas J. Philipson, 2002. "The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry," NBER Working Papers 9303, National Bureau of Economic Research, Inc.
  15. Jaffe, Adam B, 1988. "Demand and Supply Influences in R&D Intensity and Productivity Growth," The Review of Economics and Statistics, MIT Press, vol. 70(3), pages 431-37, August.
  16. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
  17. Needham, Douglas, 1975. "Market Structure and Firms' R & D Behavior," Journal of Industrial Economics, Wiley Blackwell, vol. 23(4), pages 241-55, June.
  18. Yin, Wesley, 2008. "Market incentives and pharmaceutical innovation," Journal of Health Economics, Elsevier, vol. 27(4), pages 1060-1077, July.
Full references (including those not matched with items on IDEAS)

Citations

Lists

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

Statistics

Access and download statistics

Corrections

When requesting a correction, please mention this item's handle: RePEc:ern:wpaper:03-2009. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: ().

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.